• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Myeloma - Articles and news items

daratumumab

Janssen submits application to the EMA to expand use of DARZALEX® (daratumumab)

Industry news / 24 August 2016 / Janssen-Cilag International NV

Phase 3 data supporting submission suggests potential clinical benefit of daratumumab as a backbone therapy in combination with either a proteasome inhibitor (PI) or an immunomodulatory agent for relapsed multiple myeloma patients…

edo-s101

First-in-human trial of MundiPharma’s EDO-S101 starts

Industry news / 14 July 2016 / Victoria White, Digital Content Producer

A first in class, fusion molecule, S101 is currently being developed for the treatment of relapsed-refractory haematological malignances…

kyprolis

EC approves extended indication for Kyprolis in multiple myeloma

Industry news / 4 July 2016 / Victoria White, Digital Content Producer

The EC has approved a variation to the marketing authorisation for Amgen’s Kyprolis (carfilzomib) to include use in combination with dexamethasone alone…

nkr-2

First patient treated in fourth dose level NKR-2 Phase I/IIa trial

Industry news / 23 June 2016 / Victoria White, Digital Content Producer

The study is evaluating Celyad’s NKR-2 T-cell therapy using T-cells with NKG2D receptor in patients suffering from AML or multiple myeloma…

kyprolis

Amgen presents new data for Kyprolis in multiple myeloma at EHA

Industry news / 13 June 2016 / Victoria White, Digital Content Producer

A post-hoc analysis of the Phase III ASPIRE study highlighted the benefit of continued treatment with Kyprolis, lenalidomide and dexamethasone (KRd)…

Daratumumab

Daratumumab significantly extends PFS in multiple myeloma study

Industry news / 10 June 2016 / Victoria White, Digital Content Producer

A Phase III trial shows daratumumab in combination with lenalidomide and dexamethasone achieved a 63% reduction in the risk of disease progression or death…

daratumumab

Daratumumab extends PFS in patients with multiple myeloma

Industry news / 6 June 2016 / Victoria White, Digital Content Producer

Daratumumab, in combination with bortezomib and dexamethasone, demonstrated a 61% reduction in the risk of disease progression or death…

Kyprolis

Amgen receives positive CHMP opinion to extend indication of Kyprolis

Industry news / 27 May 2016 / Victoria White, Digital Content Producer

The CHMP has adopted a positive opinion to extend the indication for Kyprolis to include treatment in combination with dexamethasone in multiple myeloma…

daratumumab

EC grants conditional approval to daratumumab in multiple myeloma

Industry news / 23 May 2016 / Victoria White, Digital Content Producer

Daratumumab is the first CD38-directed mAb approved in Europe. It binds to CD38, a signalling molecule expressed on the surface of multiple myeloma cells…

empliciti

EC approves Empliciti as combination therapy for multiple myeloma

Industry news / 12 May 2016 / Victoria White, Digital Content Producer

Empliciti (elotuzumab) is approved for use with Revlimid (lenalidomide) and dexamethasone in patients who have received at least one prior therapy…

Daratumumab

Daratumumab combination improves PFS in multiple myeloma study

Industry news / 1 April 2016 / Victoria White

Daratumumab combination treatment regimen improved progression-free survival compared with bortezomib and dexamethasone alone…

nkr-2

Celyad posts an update on its NKR-2 Trial

Industry news / 30 March 2016 / Victoria White

Celyad has announced the completion of the safety follow-up of the first patient in the third dose level in the Phase I/IIa of its NKR-2 T-cell therapy…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +